Trials / Completed
CompletedNCT01612676
Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock
An Open Label Feasibility Trial Investigating FE 202158 as Potential Primary Vasopressor Treatment in Patients With Vasodilatory Hypotension in Early Septic Shock.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to investigate the potential of FE 202158 as a treatment which can stabilize blood pressure for treatment of patients in early septic shock.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FE 202158 |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2013-11-01
- Completion
- 2013-11-01
- First posted
- 2012-06-06
- Last updated
- 2017-03-23
- Results posted
- 2017-01-16
Locations
4 sites across 2 countries: Belgium, Denmark
Source: ClinicalTrials.gov record NCT01612676. Inclusion in this directory is not an endorsement.